How Structural Shifts in Medtech Are Reshaping Europe's Industrial Competitiveness

Clarivate's 2026 medtech outlook identifies five structural forces — pricing reform in China, the migration of procedures to outpatient settings, supply chain pressure, GLP-1 adoption and platform-based competition — each of which carries direct consequences for European manufacturers, health systems and investors.

Executive Summary

• Clarivate's Medtech Trends to Watch 2026 identifies five forces reshaping global device markets: the expansion of China's volume-based procurement (VBP), the migration of procedures into outpatient and ambulatory surgical centre (ASC) settings, trade and supply chain pressure, the rapid adoption of GLP-1 therapies, and a shift toward platform-based competition built on robotics, imaging, navigation and digital workflow software.
• Each force alters a different variable of competitiveness: price formation, site of care, cost structure, clinical pathway and value capture. Combined, they narrow the margin for error in portfolio strategy, manufacturing footprint and commercial execution.
• Europe's exposure is structural rather than incidental. The region combines a large device manufacturing base, a high share of small and mid-sized suppliers, an export-oriented trade profile and a regulatory framework widely regarded as among the most demanding globally.
• Pricing pressure originating in China and reimbursement change in the United States travel quickly through global reference pricing, tender design and investor expectations, even where European procurement rules differ.
• The strategic responses most likely to define the next cycle are platform consolidation, manufacturing and sourcing diversification, deeper localisation in large markets, and heavier investment in data and software capabilities.
• The analysis below draws on Clarivate's published 2026 outlook. The European implications are EuroBizHerald's assessment.

Introduction

The medical technology sector is entering a period in which competitive advantage depends less on individual device performance and more on how companies are positioned within pricing systems, care settings, supply chains and software ecosystems. Clarivate's 2026 outlook frames this as a set of structural forces rather than a cyclical downturn or a single technological wave, and that framing matters for how European businesses should read the year ahead.

Europe's position in this landscape is distinctive. It hosts globally significant imaging, diagnostics, orthopaedics, cardiology and surgical equipment manufacturers, alongside thousands of suppliers and specialist engineering firms that feed into device production. It is also a large net exporter of medical technology and a major importer of intermediate components. That combination means European companies are exposed simultaneously to demand-side reforms in export markets and supply-side cost shocks at home.

At the same time, the European policy environment is itself in transition. Medical device and in vitro diagnostic regulation, the emerging European Health Data Space, the phased application of artificial intelligence rules to medical software, and joint clinical assessment for health technology evaluation all shape the cost and speed at which products reach European patients. Understanding the five forces in the Clarivate outlook therefore requires reading them alongside Europe's own regulatory and industrial agenda.

Main Analysis

1. Pricing power shifts as China's VBP model matures

China's latest national volume-based procurement round represents one of the most consequential developments in global medtech pricing. According to Clarivate, the programme was originally intended to expand patient access and curb high device costs, but has evolved into a market-structuring mechanism. The newest rules introduce more sophisticated anchor-price logic, deeper price compression and allocation systems that support domestic manufacturers.

The critical point for multinationals is that VBP can no longer be treated as a localised policy question. It influences expectations around price, volume and competitive positioning in markets well beyond mainland China, because procurement authorities, payers and investors use comparable benchmarks when assessing device value.

For European manufacturers with meaningful revenue exposure in China — particularly in imaging, orthopaedics, cardiology and diagnostics — the practical consequences include pressure on price realisation, a rebalancing of portfolios toward segments less exposed to tendered categories, and difficult decisions about local manufacturing. Localisation can preserve market access, but it also shifts production and associated employment away from European sites, which has implications for the region's industrial base and for policy discussions about reciprocity in public procurement.

2. Care delivery moves out of the hospital

The migration of procedures from inpatient hospitals to outpatient departments and ambulatory surgical centres continues to reshape procedure economics. Clarivate points to the 2026 Hospital Outpatient Prospective Payment System and ASC Payment System final rule issued by the US Centers for Medicare & Medicaid Services, which expands the ASC covered procedure list and phases out the inpatient-only list. That opens the door for higher-acuity procedures, including cardiac ablation, to move into lower-cost settings where clinically appropriate, building on patterns already established in orthopaedics and general surgery.

The commercial implication is that device makers must serve a more fragmented customer base. ASCs typically have different capital budgets, sterilisation capacity, staffing models and tolerance for complexity than large hospital systems. Products designed for high-volume hospital workflows may need to be reconfigured — smaller footprints, single-use or simplified instrument sets, financing and service arrangements that fit lower-capital buyers.

Europe's reimbursement landscape is more fragmented than the US system, but the direction of travel is similar. Fiscal pressure on health systems, waiting-list backlogs and explicit day-surgery targets in several countries all point toward more procedures being delivered outside traditional inpatient settings, even if payment mechanisms differ by member state. Manufacturers that treat site-of-service strategy as a US-only exercise risk misreading their own home markets.

3. Trade and supply chain pressure becomes a cost-structure question

Tariff exposure, geopolitical tension and fluctuating input costs are challenging long-standing assumptions about where and how devices should be produced. Clarivate notes that these pressures are prompting companies to diversify sourcing, reassess business strategy and pursue more flexible multi-region manufacturing footprints. Larger manufacturers are using scale, integration and technology investment to buffer volatility — a dynamic that could further reshape competitive positions across categories.

The strategic significance extends beyond logistics. Cost structure, supplier concentration, manufacturing geography and portfolio rebalancing increasingly influence competitive advantage in their own right, not merely as inputs to product performance.

For Europe, three features of the supply chain debate stand out. First, several critical inputs and components are concentrated in a small number of jurisdictions, which exposes European assembly operations to single-point disruption. Second, energy and compliance costs shape the economics of domestic production, particularly for energy-intensive processes such as sterilisation and certain polymer and metal treatments. Third, regulatory requirements for device traceability and post-market surveillance place a premium on supplier visibility, which favours manufacturers able to map their supply chains in detail. Central and Eastern European manufacturing locations, Ireland's concentrated device cluster and established industrial districts in Germany, Italy and France are all part of the equation as companies reconsider footprint decisions.

4. GLP-1 therapies redraw clinical and commercial pathways

The rapid adoption of glucagon-like peptide-1 receptor agonists is altering how patients and clinicians approach weight management and related comorbidities. Clarivate notes that while bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1 therapies have expanded quickly in popularity, changing referral patterns and influencing demand across adjacent device categories.

The impact is not uniform. Some bariatric procedures are experiencing sharper volume pressure than others, and downstream effects — spanning diabetes care, sleep apnoea and cardiovascular monitoring — are only beginning to emerge. This heterogeneity matters for portfolio planning: broad assumptions about an obesity-drug effect on device demand are less useful than procedure-level and indication-level analysis.

European health systems face a substantial metabolic disease burden and are simultaneously evaluating reimbursement for GLP-1 therapies under constrained budgets. That creates a two-sided effect. Pressure on some surgical device volumes is likely to intensify in markets where pharmaceutical reimbursement expands fastest, while demand could rise for diagnostic, monitoring and imaging technologies used to manage patients on long-term therapy. European diagnostics and digital health suppliers may find opportunities in structured follow-up and comorbidity tracking, provided they can demonstrate value to payers.

5. Platform competition replaces product competition

Across medical technology, enabling technologies — robotics, imaging, navigation and digital workflow software — are reshaping how companies differentiate. Clarivate argues that these technologies are no longer adjuncts to procedures but central components of integrated ecosystems supporting clinical planning, surgical execution and postoperative care. Companies are investing heavily in platform architectures intended to anchor entire service lines, strengthen customer relationships and unlock data-driven value propositions, while emerging open-platform systems expand flexibility and create new competitive dynamics.

Europe has credible foundations here: strong imaging and industrial automation capabilities, deep engineering talent in medical device clusters, and a research base that generates substantial clinical and technical output. The constraint is commercial scaling. Platform competition rewards installed bases, software iteration speed, data access and long-duration capital — areas where European ventures have historically faced tighter funding and slower procurement cycles than US counterparts.

Regulation cuts both ways. Detailed clinical evidence requirements and high data protection standards can slow deployment, but they also create a defensible quality baseline. The European Health Data Space, designed to facilitate secondary use of health data under strict governance, and the application of artificial intelligence rules to medical software, will shape which platform strategies are viable. Companies that build compliance and data governance into product architecture early are likely to face lower friction than those treating them as afterthoughts.

Business Impact

Competitiveness. The combination of procurement-driven price compression in China, site-of-service shifts and reimbursement scrutiny in Western markets compresses the traditional model of premium pricing justified by incremental device improvement. Differentiation is migrating toward workflow integration, evidence generation and total cost of care.

Corporate strategy. Portfolio reviews are likely to prioritise categories with durable pricing and clear clinical pathways, while underperforming or heavily tendered lines become candidates for divestment or partnership.

Manufacturing and employment. Multi-region manufacturing raises fixed costs but reduces concentration risk. Decisions on where to locate production will increasingly weigh energy costs, regulatory predictability, labour availability and proximity to large purchasing markets, with consequences for regional employment in established device clusters.

Foreign direct investment. Localisation requirements in large markets and the search for resilient supply chains both influence investment flows. Europe's ability to attract and retain device investment will depend on permitting speed, energy competitiveness and the predictability of its regulatory framework.

SMEs and suppliers. Smaller firms, which form a large share of Europe's device ecosystem, are disproportionately affected by compliance costs, supply chain visibility requirements and buyer consolidation. Access to shared testing infrastructure, contract manufacturing capacity and digital tooling becomes a determinant of survival.

Capital markets and innovation funding. Platform-based competition requires longer investment horizons than single-product development. That favours investors able to fund clinical evidence generation and software development simultaneously, and may accelerate consolidation of smaller innovators into larger groups.

Supply chains. Dual sourcing, buffer inventory and supplier mapping are becoming standing capabilities rather than crisis responses, with implications for working capital and pricing.

Technology adoption. Robotics, navigation and digital workflow tools are moving from optional differentiators to procurement prerequisites in some service lines, raising the capital intensity of both manufacturers and healthcare providers.

Long-term resilience. Companies that integrate regulatory, data and supply chain capabilities into core strategy are better positioned to absorb the next wave of pricing, trade and clinical disruption.

European Perspective

At the European Union level, the policy agenda intersects with each of the five forces. Device and diagnostics regulation sets the compliance baseline; competition and procurement rules shape market access; trade instruments reflect growing attention to reciprocity in public purchasing, including scrutiny of medical device procurement in China under the EU's International Procurement Instrument. Joint clinical assessment for health technology evaluation, phased in under the EU HTA framework, will gradually change how evidence is assessed across member states and could reduce duplication while raising the bar for data quality.

Germany remains Europe's largest device market and manufacturing base, with particular strength in imaging, surgical instruments and industrial medical engineering. Its exposure to Chinese pricing reform and to global tender competition is significant, and its cost base makes manufacturing footprint decisions especially sensitive. France combines strong diagnostics and imaging capabilities with an active industrial policy focused on healthcare sovereignty. Italy's device sector, heavily reliant on specialised small and mid-sized firms, faces the sharpest adaptation challenge on compliance and consolidation. Spain is building capability in digital health and clinical research infrastructure. The Nordic countries bring strengths in digital health, registry data and outcomes-based procurement.

Central and Eastern Europe has become an important manufacturing location for medical devices and components, supported by skilled labour and proximity to Western European markets. Further investment in the region is plausible if companies pursue multi-region footprints, though it will depend on infrastructure, energy costs and workforce availability.

The Single Market remains Europe's principal structural advantage: a large, regulated home market that supports scale in evidence generation and manufacturing. Cross-border cooperation on health data, joint procurement and clinical trials could strengthen that advantage, but progress depends on implementation capacity in member states.

Future Outlook

Over the next three to five years, several developments appear probable, though timing and intensity will vary by market.

Artificial intelligence and software. AI-enabled clinical decision support, imaging analysis and surgical workflow tools are likely to move from pilot programmes to routine deployment in leading European hospitals. Regulatory clarity under the EU AI Act, combined with device regulation, will determine which developers can scale across member states.

Industrial policy. European and national programmes focused on healthcare resilience, critical inputs and advanced manufacturing are likely to continue, with emphasis on reducing single-point dependencies and supporting domestic production of essential components.

Trade and supply chains. Tariff regimes and procurement reciprocity will remain volatile. Companies should expect continued pressure to localise in large markets while maintaining diversified supplier networks, with cost implications that will not fully pass through to payers.

Clinical pathways. GLP-1 adoption will continue to reshape metabolic disease management, with downstream effects on bariatric procedure volumes, monitoring devices and diagnostics. Clinical guidelines and reimbursement decisions will be the main transmission channels.

Platform competition. Robotics, navigation and digital workflow integration will determine leadership in several surgical categories. Open platforms may lower barriers for smaller innovators while increasing pressure on proprietary ecosystems to demonstrate measurable outcomes.

Capital markets. European medtech financing will depend on the availability of long-duration capital, the depth of exit markets and investor appetite for evidence-heavy development timelines. Public instruments and partnerships between industry, universities and health systems are likely to play a larger role in early-stage funding.

Sustainability and manufacturing. Energy transition, circular economy rules for single-use devices and carbon reporting requirements will increasingly influence production costs and procurement criteria, especially where health systems embed sustainability conditions in tenders.

Europe's global position. Maintaining competitiveness will depend less on defending legacy advantages than on executing faster in software, evidence generation and supply chain resilience while preserving the regulatory credibility that underpins European market access worldwide.

Conclusion

The five forces identified in Clarivate's 2026 medtech outlook describe a sector where advantage is determined by position within systems rather than by products alone. Procurement rules set prices, payment rules set sites of care, trade policy sets cost structures, pharmaceutical innovation sets clinical pathways, and software platforms set long-term customer relationships.

For European manufacturers, the practical agenda is unglamorous but consequential: rationalise portfolios around defensible categories, invest in software and evidence capabilities, diversify manufacturing and sourcing, and treat regulatory compliance as a design input rather than a cost centre. For European policymakers, the agenda is equally concrete: preserve a predictable regulatory environment, accelerate the deployment of shared health data infrastructure, and ensure that industrial and trade instruments support rather than fragment a single market that remains the region's most valuable competitive asset.

Key Takeaways

• China's expanding volume-based procurement has moved beyond a domestic pricing policy and now influences global expectations on price, volume and competitive positioning.
• The migration of procedures into outpatient and ambulatory surgical centre settings requires different products, commercial models and financing arrangements, and is not confined to the United States.
• Supply chain resilience has become a cost-structure and competitive advantage issue, pushing manufacturers toward multi-region footprints and dual sourcing.
• GLP-1 adoption is reshaping metabolic disease pathways unevenly, with differentiated effects across bariatric, diagnostic, monitoring and cardiovascular device categories.
• Platform competition in robotics, imaging, navigation and digital workflow software is raising the capital and evidence intensity of the sector.
• Europe's response will be determined by regulatory predictability, health data infrastructure, energy and compliance costs, and the depth of long-duration capital available to its device and software developers.

SEO Keywords

Europe business, European economy, European Union, Single Market, industrial policy, medical technology, medtech trends 2026, value-based procurement, supply chain resilience, foreign direct investment, manufacturing, innovation, capital markets, technology, economic growth, European competitiveness, digital health, artificial intelligence, health data, Green Deal, energy transition, infrastructure, business strategy.

Sources

• Clarivate, 5 medtech trends to watch in 2026 (28 April 2026) — https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026
• Clarivate, Medtech Trends to Watch 2026 (report landing page) — https://clarivate.com/life-sciences-healthcare/lp/medtech-trends-to-watch-in-2026/
• European Commission, Medical Devices sector — https://health.ec.europa.eu/medical-devices-sector_en
• European Commission, European Health Data Space — https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en
• European Commission, Regulatory framework for artificial intelligence — https://digital-strategy.ec.europa.eu/en/policies/regulatory-framework-ai
• US Centers for Medicare & Medicaid Services, Prospective payment systems — https://www.cms.gov/medicare/payment/prospective-payment-systems
• European Commission, Directorate-General for Trade — https://policy.trade.ec.europa.eu/index_en

External links are provided for reference. Data and market observations attributed to Clarivate originate in the cited material; all other statements are EuroBizHerald's editorial assessment based on publicly available information.